{"id":"NCT00479388","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Study of Extended Release Niacin/Laropiprant on Lipids (0524A-067)","officialTitle":"A Multicenter, Randomized, Double-Blind, Parallel Group, 12 Week Study to Evaluate the Efficacy and Safety of Extended-release (ER) Niacin/Laropiprant in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-07","primaryCompletion":"2008-07","completion":"2008-10","firstPosted":"2007-05-28","resultsPosted":"2009-07-31","lastUpdate":"2015-03-10"},"enrollment":1216,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Primary Hypercholesterolemia","Mixed Dyslipidemia"],"interventions":[{"type":"DRUG","name":"Comparator: simvastatin","otherNames":["ZocorÂ®"]},{"type":"DRUG","name":"niacin (+) laropiprant","otherNames":["MK0524A"]},{"type":"DRUG","name":"Comparator: atorvastatin calcium","otherNames":["atorvastatin"]}],"arms":[{"label":"1","type":"OTHER"},{"label":"2","type":"ACTIVE_COMPARATOR"}],"summary":"This is a 12-Week clinical trial in patients with Primary hypercholesterolemia or mixed dyslipidemia to study the effects of ER niacin/laropiprant on lipids.","primaryOutcome":{"measure":"Percent Change From Baseline in Low Density Lipoprotein Cholesterol at Week 12","timeFrame":"Baseline and 12 Weeks","effectByArm":[{"arm":"ER Niacin/Laropiprant + Run-in Statin","deltaMin":-10,"sd":null},{"arm":"Run-in Statin Dose Doubled","deltaMin":-5.5,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.006"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":1},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["20518948","22500948","21401833"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":14},"commonTop":["Flushing","Pruritus","Nausea","Nasopharyngitis","Diarrhoea"]}}